The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The promise of momelotinib in the treatment of myelofibrosis
Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of momelotinib in the treatment of myelofibrosis (MF), highlighting the anemia benefit observed in patients receiving this agent. Dr Bose also discusses clinical trials which have evaluated the efficacy of momelotinib, including the SIMPLIFY-1 and SIMPLIFY-2 trials (NCT01969838, NCT02101268) and the MOMENTUM trial (NCT04173494), and further comments on the value of adding momelotinib to the MF treatment armamentarium. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
